| P2093 | author name string | Anja Bastian | |
| | Aleem Gangjee | |
| | Rheal A Towner | |
| | Debra Saunders | |
| | Nataliya Smith | |
| | Michael Ihnat | |
| | Roheeth Kumar Pavana | |
| P2860 | cites work | Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. | Q54623906 |
| | Paclitaxel (TAXOL®) concentrations in brain tumor tissue | Q72109363 |
| | Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent | Q27679191 |
| | Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 | Q28487568 |
| | CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. | Q30402063 |
| | CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 |
| | Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential | Q33636107 |
| | Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery | Q33816457 |
| | Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. | Q33981559 |
| | Glioma morphology and tumor‐induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography | Q34041524 |
| | Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology | Q34132943 |
| | Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model | Q34198939 |
| | Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches | Q34515465 |
| | Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers | Q34815207 |
| | The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma | Q35053326 |
| | Novel therapies in glioblastoma | Q35864136 |
| | Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression | Q36193529 |
| | ELTD1, a potential new biomarker for gliomas | Q36564447 |
| | Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. | Q36627197 |
| | Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI. | Q37510240 |
| | Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases | Q37544152 |
| | Current therapeutic paradigms in glioblastoma | Q37703345 |
| | Glioma proteomics: status and perspectives. | Q37717824 |
| | Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. | Q39717688 |
| | MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? | Q39834203 |
| | Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. | Q40265290 |
| | Drug resistance in brain tumors | Q40560888 |
| | Induction of O6-methylguanine-DNA-methyltransferase and N3-methyladenine-DNA-glycosylase in human cells exposed to DNA-damaging agents | Q41561865 |
| | Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. | Q45003993 |
| | Combined molecular MRI and immuno-spin-trapping for in vivo detection of free radicals in orthotopic mouse GL261 gliomas | Q45777378 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 522 | |
| P577 | publication date | 2015-07-17 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model | |
| P478 | volume | 15 | |